Research location
Neo Faliro
Greece
Advertisement
Research activity in Neo Faliro
GreeceCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Neo Faliro
16 linked trials · page 1 of 1Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24 · 1 site observation
RECRUITING
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340 · 2022-03-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyNCT04151563 · 2021-04-15 · 1 site observation
WITHDRAWN
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung CancerNCT05761977 · 2021-03-31 · 1 site observation
UNKNOWN
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerNCT04475939 · 2020-10-26 · 1 site observation
COMPLETED
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826 · 2015-08-05 · 1 site observation
COMPLETED
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsNCT01905592 · 2014-02-25 · 1 site observation
TERMINATED
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung CancerNCT01362296 · 2011-09-01 · 1 site observation
COMPLETED
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerNCT00820222 · 2009-04-14 · 1 site observation
COMPLETED
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung CancerNCT00789373 · 2008-11-01 · 1 site observation
COMPLETED
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerNCT00480025 · 2007-10-04 · 1 site observation
TERMINATED
Brain Metastases In ErbB2-Positive Breast CancerNCT00437073 · 2007-05-01 · 1 site observation
TERMINATED
Lapatinib for Brain Metastases In ErbB2-Positive Breast CancerNCT00263588 · 2005-12-02 · 1 site observation
COMPLETED
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerNCT00320385 · 2005-11-01 · 1 site observation
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT00949910 · 2004-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.